Home Mailto



The EuroSIDA study is a prospective observational cohort study of more than 18791 patients followed in 108 hospitals in 34 European countries plus Israel and Argentina. The main objective of the study is to assess the impact of antiretroviral drugs o­n the outcome of the general population of HIV-infected patients living in Europe.

Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773), the 6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/2007-2013, EuroCoord n° 260694) programmes. Current support also includes unrestricted grants by Bristol-Myers Squibb, Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787).

CONTACT information

Co-Project Leaders: Ole Kirk and Amanda Mocroft

Data Manager: Rikke Salbøl Brandt rsb@cphiv.dk

Coordinating Centre Staff:
Kamilla Grønborg Laut kgl@cphiv.dk
Charlotte Matthews cma@cphiv.dk
Jette Nielsen jen@cphiv.dk
Annette Fischer ahf@cphiv.dk
Ane Bojesen abo@cphiv.dk

Updated: 08 Apr 2014